2022 article
Prevalence of aldosterone breakthrough in dogs receiving renin-angiotensin system inhibitors for proteinuric chronic kidney disease
Ames, M. K., Vaden, S. L., Atkins, C. E., Palerme, J.-S., Langston, C. E., Grauer, G. F., … Webb, T. (2022, November 9). JOURNAL OF VETERINARY INTERNAL MEDICINE.
author keywords: mineralocorticoid receptor antagonists; nephrology; renin-angiotensin-aldosterone system; urine aldosterone to creatinine ratio
MeSH headings : Dogs; Animals; Aldosterone; Renin-Angiotensin System / physiology; Creatinine / urine; Prospective Studies; Prevalence; Antihypertensive Agents / therapeutic use; Proteinuria / drug therapy; Proteinuria / veterinary; Renal Insufficiency, Chronic / drug therapy; Renal Insufficiency, Chronic / veterinary; Dog Diseases / drug therapy
TL;DR:
Whether ABT occurs in dogs with CKDP and if it is associated with decreased efficacy in proteinuria reduction during RAS inhibitor treatment is investigated and its relationship with outcomes is evaluated.
(via Semantic Scholar)
open access via onlinelibrary.wiley.com (publisher PDF)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Source: Web Of Science
Added: November 21, 2022
AbstractBackgroundThe influence of aldosterone breakthrough (ABT) on proteinuria reduction during renin‐angiotensin system (RAS) inhibition for spontaneous proteinuric chronic kidney disease (CKDP) has not been determined in dogs.ObjectivesDetermine whether ABT occurs in dogs with CKDP and if it is associated with decreased efficacy in proteinuria reduction during RAS inhibitor treatment.AnimalsFifty‐six client‐owned dogs with CKDP and 31 healthy client‐owned dogs.MethodsProspective, multicenter, open‐label clinical trial. Dogs were treated with an angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker alone or in combination at the attending clinician's discretion and evaluated at 5 time points over 6 months. Healthy dogs were used to determine the urine aldosterone‐to‐creatinine ratio cutoff that defined ABT. The relationship of ABT (present at ≥50% of visits) and proteinuria outcome (≥50% reduction in urine protein‐to‐creatinine ratio from baseline at ≥50% of subsequent visits) was evaluated. Mixed effects logistic regression was used to evaluate the relationship between clinical variables and outcomes (either successful proteinuria reduction or ABT).ResultsThirty‐six percent (20/56) of dogs had successful proteinuria reduction. Between 34% and 59% of dogs had ABT, depending on the definition used. Aldosterone breakthrough was not associated with proteinuria outcome. Longer duration in the study was associated with greater likelihood of successful proteinuria reduction (P = .002; odds ratio, 1.6; 95% confidence interval [CI], 1.2‐2.2).Conclusions and Clinical ImportanceAldosterone breakthrough was common in dogs receiving RAS inhibitors for CKDp but was not associated with proteinuria outcome.